A combination of gemcitabine and 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD)

British Journal of Cancer

Volumn 80, Issue 10, 1999, Pages 1595-1598

  Cascinu, S ^a   Silva, R R ^b   Barni, S ^c   Labianca, R ^d   Frontini, L ^e   Piazza, E ^f   Pancera, G ^g   Giordani, P ^a   Giuliodori, L ^b   Pessi, M A ^d   Fusco, V ^h   Luporini, G ^d   Cellerino, R ⁱ   Catalano, G ^a  

^a Azienda Ospedaliera Osp S S   (Italy)

^b Ospedale di Fabriano   (Italy)

^c SAN GERARDO HOSPITAL   (Italy)

^d SAN CARLO BORROMEO HOSPITAL   (Italy)

^e SAN PAOLO HOSPITAL   (Italy)

^f UNIVERSITY OF MILAN   (Italy)

^g Medical Oncology   (Italy)

^h Ospedale Civile   (Italy)

ⁱ UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

Intensive chemotherapy; Palliation; Pancreatic cancer

Indexed keywords

FLUOROURACIL; GEMCITABINE; PYRIMIDINE ANTAGONIST;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIARRHEA; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ITALY; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 0033029525     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690568     Document Type: Article

References (22)

1. Ahlgren JD (1996) Chemotherapy for pancreatic cancer. Cancer 78: 654-663
2. Burris III HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD and Von Hoff DD (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403-2413
3. Carmichael J, Fink U, Russel RCG, Spittle MF, Harris A and Spiessl G (1995) Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer 73: 101-105
4. Casper ES, Green MR, Kelsen DP, Heelan RT, Brown TD and Flombaum CD (1994) Phase II trial of gemcitabine in patients with adenocarcinoma of the pancreas. Invest New Drug 12: 29-35
5. DeCaprio JA, Mayer RJ, Gonin R and Arbuck SG (1991) Fluorouracil and high-dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas; results of a phase II trial. J Clin Oncol 9: 2128-2133
6. Grindey GB, Hertel LW and Plunkett W (1990) Cytotoxicity and antitumor activity of 2′,2′-difluorodeoxycitidine (Gemcitabine). Cancer Invest 8: 313-318
7. Heinemann V, Xu YZ, Chubb S, Sen A, Hertel LW, Grindey GB and Plunkett W (1991) Inhibition of ribonucleotide reductase in CCRF-CEM cells by 2′,2′-difluorodeoxycitidine. Mol Pharmacol 38: 567-572
8. Kelly DM and Benjamin IS (1995) Pancreatic carcinoma. Ann Oncol 6: 19-28
9. Lionetto R, Pugliese V, Bruzzi P and Rosso R (1995) No standard treatment is available for advanced pancreatic cancer. Eur J Cancer 6: 882-887
10. Miller AB, Hoodgstraten B, Staquet M and Winkler A (1981) Reporting results of cancer treatment. Cancer 47: 207-214
11. Moore M (1996) Activity of gemcitabine in patients with advanced pancreatic carcinoma. A review. Cancer 78: 633-638
12. Parker SL, Tong T, Bold S and Wingo PA (1997) Cancer statistics, 1997. CA Cancer Clin 47: 5-27
13. Popescu RA and Cunningham D (1997) Chemotherapy for advanced pancreatic cancer. Some lights at the end of the tunnel? Ann Oncol 8: 415-416
14. Rothenberg ML, Abbruzzese JL, Moore M, Portenoy RK, Robertson JM and Wanebo HJ (1996) A rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinoma. Cancer 78: 627-632
15. Rothenberg LM, Moore MJ, Cripps MC, Andersen JS, Portenoy RK, Burris III HA, Green MR, Tarassoff PG, Brown TD, Casper ES, Stomiolo AM and Von HolT DD (1996) A phase II trial of gemcitabine in patients with 5FU-refractory pancreas cancer. Ann Oncol 7: 347-353
16. Rougier P, De Forni M, Adenis A, Ducreux M, Djazouli K, Adams D, Bonneterre J, Clouet P, Blanc C, Bayssas M and Armand JP (1994) Phase II study of taxotere in pancreatic adenocarcinoma. Proc Am Soc Clin Oncol 13: 200
17. Schnall S and Macdonald JS (1996) Chemotherapy of adenocarcinoma of the pancreas. Semin Oncol 23: 220-228
18. Scher MN, Kosierowski R, Lusch C, Alexander R, Fox S, Redei I, Green F, Raskay B, Amfoh K, Engstrom PF and O'Dwyer PJ (1996) Phase II trial of topotecan in advanced or metastatic adenocarcinoma of the pancreas. Invest New Drugs 13: 347-354
19. Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10: 1-10
20. Taylor I (1993) Should further studies of chemotherapy be carried out in pancreatic cancer? Eur J Cancer 29: 1076-1078
21. Wagener DJT, Verdonk HER, Dirix LY, Catimel G, Siegenthaler P, Buitenhuis M, Mathieu-Boué A and Verweij J (1995) Phase II trial of CPT11 in patients with advanced pancreatic cancer, an EORTC early clinical trial group study. Ann Oncol 6: 129-132
22. Whitehead RP, Jacobson J, Brown TD, Taylor SA, Weiss, GR and Macdonald JS (1997) Phase II trial of paclitaxel and granulocyte colony-stimulating factor in patients with pancreatic carcinoma: A Southwest Oncology Group Study. J Clin Oncol 15: 2414-2419